AMG 837 calcium hydrate 是GPR40/FFA1的有效的、具有口服活性的部分激动剂,抑制 [3H]AMG 837 与人类FFA1受体的特异性结合,pIC50值为 8.13。AMG 837 calcium hydrate 可增强啮齿动物的胰岛素分泌并降低葡萄糖水平。
生物活性 | AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist ofGPR40/FFA1. AMG 837 calcium hydrate inhibits specific [3H]AMG 837 binding at the human FFA1 receptor with apIC50of 8.13. AMG 837 calcium hydrate could enhanceinsulinsecretion and lower glucose levels in rodents[1][2][3]. |
IC50& Target | |
体外研究 (In Vitro) | AMG 837 (1 nM-10 μM) stimulates insulin secretion in a glucose-dependent manner with an EC50of 142±20 nM on islets isolated from mice[1]. AMG 837 stimulates Ca2+flux with theEC50s of 13.5, 22.6 and 31.7 nM for human, mouse and rat receptors in CHO cells, respectively[1].
|
体内研究 (In Vivo) | AMG 837 (0.03-0.3 mg/kg; p.o. once daily for 21 days) reduces glucose levels and increases insulin levels following glucose challenge in vivo[1]. AMG 837 (0.03-0.3 mg/kg; a single p.o.) improves glucose tolerance and enhances insulin secretion in Sprague-Dawley rats[1]. AMG 837 (0.5 mg/kg; p.o.) displays excellent oral bioavailability (F = 84%) and a total plasma Cmaxof 1.4 μM[1].
Animal Model: | 8-week old Zucker Fatty Rats[1] | Dosage: | 0.03, 0.1, 0.3 mg/kg | Administration: | Oral gavage once daily for 21 days | Result: | Decreased glucose AUC values during the glucose tolerance test (GTT) to 7%, 15%, and 25% at 0.03, 0.1 and 0.3 mg/kg, respectively. Increased insulin levels in the mid- and high-dose groups. Not affected body weights during the 21-day treatment. |
Animal Model: | 8-week old Sprague-Dawley rats[1] | Dosage: | 0.03, 0.1, 0.3 mg/kg | Administration: | A single p.o. administration | Result: | Reduced the post-prandial glucose with the half-maximal dose of 0.05 mg/kg. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : ≥ 42 mg/mL(92.22 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.1956 mL | 10.9782 mL | 21.9563 mL | 5 mM | 0.4391 mL | 2.1956 mL | 4.3913 mL | 10 mM | 0.2196 mL | 1.0978 mL | 2.1956 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.5 mg/mL (5.49 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (5.49 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.49 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.49 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|